.jpeg "Indian Pharma Targets Rs 800 Cr Insulin Pen Market Post Novo")
Novo Nordisk's declaration to put an end to its Penfill and FlexPen products in India by December 2023, Indian pharmaceutical companies like Eris Lifesciences, Wockhardt, and Lupin, are getting ready to capitalize the local human insulin
Alkem Laboratories announced the launch of Pertuza injection 420mg/14mL, a pertuzumab biosimilar that has been developed in India and can be used in HER2-positive breast cancer. With this achievement, Alkem aims to provide better access to...
The first comprehensive worldwide framework created to guarantee access to controlled drugs for medical and scientific uses while reducing the risks to public health that may arise from misuse and diversion was released by the World Health
Akums Drugs & Pharmaceuticals highlights lacosamide, a well-established antiepileptic drug (AED), as a versatile and effective option for patients with epilepsy across age groups and clinical settings. Recognized for its broad clinical applicability,
The opening of a new glass tubing factory in Telangana by Corning Incorporated and SGD Pharma would increase pharmaceutical production in the area. The new facility will help address capacity issues and quality requirements in primary glass packaging
Pfizer Inc. revealed that it is acquiring Metsera, Inc. for $4.9 billion in cash, further enhancing its pipeline in obesity and cardio-metabolic diseases. The definitive agreement was approved unanimously by both companies' boards and is a...
Hetero Healthcare Ltd., one of the most prominent Indian pharmaceutical companies, in collaboration with Enzene Biosciences Ltd., has announced the introduction of Perzea, their cheapest biosimilar of Pertuzumab.
Biocon Biologics Ltd. (BBL), a world leader in biosimilars and part of Biocon Ltd., announced today an important achievement with the inclusion of Yesafili biosimilar on the Ontario Drug Benefit (ODB) Formulary/Comparative Drug Index...
Noida-based Jubilant Pharma Limited has shared the news that its wholly-owned subsidiary, Jubilant Pharma Limited, has wrapped up a Post-marketing Adverse Drug Experience
According to a notification, India has restricted the import of a chemical used in the pharmaceutical business until September 30 of next year
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")